Soleno Therapeutics (SLNO) Common Equity (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Common Equity data on file, last reported at $495.8 million in Q1 2026.

• Common Equity for Q1 2026 came in at $495.8 million, up 113.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $495.8 million (up 113.47% YoY), and the FY2025 annual result was $450.1 million, up 83.64% from the prior year.
• Common Equity climbed to $495.8 million in Q1 2026 per SLNO's latest filing, from $450.1 million in the prior quarter.
• Over five years, Common Equity peaked at $495.8 million in Q1 2026 and troughed at $2.6 million in Q1 2023.
• A 5-year average of $183.2 million and a median of $157.5 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 90.03% in 2023, then jumped 5333.35% in 2024.
• A 5-year view of Common Equity shows it stood at $10.3 million in 2022, then surged by 1422.1% to $157.5 million in 2023, then jumped by 55.62% to $245.1 million in 2024, then jumped by 83.64% to $450.1 million in 2025, then rose by 10.15% to $495.8 million in 2026.
• Business Quant data shows SLNO's Common Equity at $495.8 million in Q1 2026, $450.1 million in Q4 2025, and $494.8 million in Q3 2025.